Australia's most trusted
source of pharma news
Tuesday, 25 November 2025
Posted 25 November 2025 PM
Omico has released its impact report outlining how its facilitation of precision oncology treatment has led to a huge boost to Australian health.
People with incurable cancer, such as metastatic bile duct, ovarian, and triple negative breast cancers, live up to 50 per cent longer when matched via DNA screening to targeted treatments, an extra 14 to 21 or more months, and in some cases survival more than doubles.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.